Literature DB >> 9890741

Anaplastic thyroid carcinoma: a therapeutic challenge.

K B Ain1.   

Abstract

Anaplastic thyroid carcinoma is an extremely aggressive solid tumor that resists most therapeutic efforts and is almost always fatal. It typically arises as a terminal dedifferentiation of unrecognized long-standing differentiated thyroid carcinoma. Current chemotherapeutic agents are not capable of consistent beneficial therapeutic responses, although rare patients may gain additional months of survival. Aggressive local tumor control with surgery and external beam radiotherapy may provide palliation and delay eventual death from distant metastatic disease. This disease challenges clinicians and researchers to develop new systemic therapies as well as to aggressively treat differentiated thyroid cancers before they become anaplastic tumors.

Entities:  

Mesh:

Year:  1999        PMID: 9890741     DOI: 10.1002/(sici)1098-2388(199901/02)16:1<64::aid-ssu10>3.0.co;2-u

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  34 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

Review 2.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

3.  Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma.

Authors:  Eun Ju Ha; Jung Hwan Baek; Jeong Hyun Lee; Jae Kyun Kim; Dong Eun Song; Won Bae Kim; Suck Joon Hong
Journal:  Eur Radiol       Date:  2015-07-23       Impact factor: 5.315

Review 4.  The "next-generation" knowledge of papillary thyroid carcinoma.

Authors:  Valerio Costa; Roberta Esposito; Pierlorenzo Pallante; Alfredo Ciccodicola; Alfredo Fusco
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

6.  Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.

Authors:  Weibin Wang; Helen Kang; Yinu Zhao; Irene Min; Brian Wyrwas; Maureen Moore; Lisong Teng; Rasa Zarnegar; Xuejun Jiang; Thomas J Fahey
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

7.  A novel orthotopic mouse model of human anaplastic thyroid carcinoma.

Authors:  Carmelo Nucera; Matthew A Nehs; Michal Mekel; Xuefeng Zhang; Richard Hodin; Jack Lawler; Vânia Nose; Sareh Parangi
Journal:  Thyroid       Date:  2009-10       Impact factor: 6.568

8.  A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis.

Authors:  Rosanna Cozzolino; Gaetano Calì; Maurizio Bifulco; Paolo Laccetti
Journal:  Invest New Drugs       Date:  2009-02-03       Impact factor: 3.850

9.  Anaplastic thyroid carcinoma: a therapeutic dilemma.

Authors:  Hang-Seok Chang; Kee-Hyun Nam; Woung Youn Chung; Cheong Soo Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

10.  Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

Authors:  Patricia J McLaughlin; Ian S Zagon; Sunny S Park; Andrea Conway; Renee N Donahue; David Goldenberg
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.